BridgeMD
Improving diagnostics in cervical dysplasia
EU CTIS ID: 2024-517151-12-00
What this study is testing
The aim is to initiate a blinded study to investigate, if the diagnosis of cervical precancerous lesions can be improved among postmenopausal women aged ≥ 50 years, by providing pretreatment with vaginal estrogen prior to the colposcopic examination. Thereby to reduce the disease burden and prevent cervical cancer.
- Therapeutic use (Phase IV)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Women referred for colposcopy aged ≥ 50 years and postmenopausal. • Women referred for colposcopy due to a positive HPV test and/or an abnormal cervical cytology. • Women referred for colposcopy due to previous abnormal cervical histology with minimum 6. months since last colposcopy with biopsies.
You likely can't join if
- Women with use of estrogen within the last 3 months. - Pregnancy - Women with previously amputation, conization or radiation of the cervix
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling female, 65+ years, 18-64 years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.